anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
GASH is a double blind, prospective and randomized clinical trial centered on the University of Sao Paulo General Hospital. Patients will be recruited from neurological/neurosurgical intensive care units. Appropriate ethics and regulatory approvals will be sought for all subjects, according to the International Conference on Harmonization guidelines for good clinical practice (ICH GCP). Investigators will obtain informed written consent from all patients or their legal representative. Recruitment will take place between 2018 and 2019.

Patients will be randomly assigned (1:1) to receive either glibenclamide 5mg or placebo. Coded boxes containing either 21 similar tablets of glibenclamide 5mg or placebo will be assigned a number. A computer-generated randomization code will be used to randomize patients by blocks of ten (five glibenclamide, five placebo). Each box will be identified by a code number specific and subsequently selected for distribution in ascending numerical order. Patients will start treatment as soon as possible within 96 h of the ictus, with a daily dose till the 21° day after the bleed. Trial medication consisted of one tablet a day, given orally or via a nasogastric tube. Aneurysm treatment, either by microsurgery or embolization, will be performed as soon as possible, according with the standard of care for the recruiting center. Nimodipine 60mg, every four hours, will be started on admission and continued till the 21° day after the ictus, in all patients as standard of care.

Patient's demographics, medical history and relevant investigation results will be collected. The severity of the hemorrhage will be clinically assessed by World Federation of Neurosurgical Societies grading scale and radiologically using the modified Fischer scale. At 6 months of follow up patients will be interviewed with modified Rankin scale (mRS) questionnaire (a scale that measures degree of incapacity/ dependence and mortality after neurological events) by a nurse or a physician with no knowledge of treatment allocation. Psychologists will evaluate quality of life and cognitive performance using the "short-form health survey questionnaire" (SF-36) and neuropsychological tests. The main hypothesis is that, once compared with standard of care, glibenclamide 5mg will provide better clinical outcome and additionally will decrease mortality and improve quality of life and cognitive performance after 6 months.

Sample size: It was estimated the sample size of 50 randomized patients to give 90% power at the 5% significance level (two-sided) to detect a treatment effect equivalent to an absolute increase of 7% in the proportion of patients with a favorable outcome (30-day mortality rate after subarachnoid hemorrhage approaches 50% and 25% of survivors present some degree of neurological morbidity25). This calculation was based on an ordinal analysis of the 6-month mRS (the primary outcome) assuming that the treatment effect follows a proportional odds model.
Study group 1. Subjects in this group received treatment with Artemether-Lumefantrine. Children received 2 mg/kg Artemether and 12 mg/kg Lumefrantrine with milk twice daily (or every 12 hours for 3 days.
Eligible participants will be randomized to receive 50 milligrams (mg)/300 mg DTG/3TC FDC therapy from Day 1 up to 52 weeks. Participants who complete 52 weeks of treatment will have the opportunity to continue receiving DTG/3TC FDC once daily in the continuation phase.
In postmenopausal patients with advanced breast cancer, daily doses of 0.1 mg to 5 mg letrozole suppress plasma concentrations of estradiol, estrone, and estrone sulfate by 75% to 95% from baseline with maximal suppression achieved within two-three days. Suppression is dose-related, with doses of 0.5 mg and higher giving many values of estrone and estrone sulfate that were below the limit of detection in the assays. Estrogen suppression was maintained throughout treatment in all patients treated at 0.5 mg or higher.

  


Letrozole is highly specific in inhibiting aromatase activity. There is no impairment of adrenal steroidogenesis. No clinically-relevant changes were found in the plasma concentrations of cortisol, aldosterone, 11-deoxycortisol, 17-hydroxy-progesterone, ACTH or in plasma renin activity among postmenopausal patients treated with a daily dose of letrozole 0.1 mg to 5 mg. The ACTH stimulation test performed after 6 and 12 weeks of treatment with daily doses of 0.1, 0.25, 0.5, 1, 2.5, and 5 mg did not indicate any attenuation of aldosterone or cortisol production. Glucocorticoid or mineralocorticoid supplementation is, therefore, not necessary.

  


No changes were noted in plasma concentrations of androgens (androstenedione and testosterone) among healthy postmenopausal women after 0.1, 0.5, and 2.5 mg single doses of letrozole or in plasma concentrations of androstenedione among postmenopausal patients treated with daily doses of 0.1 mg to 5 mg. This indicates that the blockade of estrogen biosynthesis does not lead to accumulation of androgenic precursors. Plasma levels of LH and FSH were not affected by letrozole in patients, nor was thyroid function as evaluated by TSH levels, T3 uptake, and T4 levels.
Cytogenetics are main predictors of outcome in patients with MDS and AML. In fact, a monosomy 5 (-5) or del5q (excluding typical 5q-syndrome) are mostly poor prognostic markers also because being frequently part of a complex karyotype. Together, these patients often do not respond to conventional chemotherapy and can only be cured by allogeneic HSCT. Nevertheless, even after transplantation the relapse rate is considerably high and in the majority of patient's relapses occur within the first year after HSCT.

Lenalidomide has been successfully used in MDS patients with del5q, irrespective of additional cytogenetic abnormalities. Furthermore, in vitro studies have demonstrated also impressive anti-proliferative effects of the compound in cell lines harbouring a monosomy 5. Therefore, it seems to be a promising compound in preventing relapse of high-risk MDS or AML patients with chromosomal abnormalities involving del5q or -5 after allogeneic HSCT. Due to its immunomodulatory action it might also be able to enhance T - or NK cell mediated graft versus leukemia effects. Nevertheless, it is unknown whether lenalidomide could modulate or enhance clinical graft versus host disease.
Up to 40 patients ineligible or not yet eligible for ART will be invited to join a focus group discussion. Patients will be eligible for selection for either in-depth interviews or focus group discussions if they have made at least one prior visit to the clinic. Selected patients will be balanced as much as possible by gender and by pre-ART status (e.g. roughly half pre-ART eligibility determined, and roughly half pre-ART eligibility indeterminate).
The immune system usually provides a defense against invading pathogenic microorganisms and any other particulate contaminants. Nonetheless, it has been recently reported that nanomaterials can evade the immune system and modulate immunological responses due to their unique physicochemical characteristics. Consequently, nanomaterial-based activation of immune components, i.e., neutrophils, macrophages, and other effector cells, may induce inflammation and alter the immune response. Here, it is essential to distinguish the acute and chronic modulations triggered by nanomaterials to determine the possible risks to human health. Nanomaterials size, shape, composition, surface charge, and deformability are factors controlling their uptake by immune cells and the resulting immune responses. The exterior corona of molecules adsorbed over nanomaterials surfaces also influences their immunological effects. Here, we review current nanoengineering trends for targeted immunomodulation with an emphasis on the design, safety, and potential toxicity of nanomaterials. First, we describe the characteristics of engineered nanomaterials that trigger immune responses. Then, the biocompatibility and immunotoxicity of nanoengineered particles are debated, because these factors influence applications. Finally, future nanomaterial developments in terms of surface modifications, synergistic approaches, and biomimetics are discussed.
Sexuality is a central aspect of being human that encompasses all life. Nurses play an important role in providing sexual health care to individuals. There is evidence in the literature that the knowledge and skills that nurses should have in order to provide sexual health care are not sufficient. The main reason why nurses have problems in the provide sexual health care is that the subject of sexuality is not sufficiently included in the undergraduate nursing education. Sexual health education programs should be structured in a way to effectively increase the competencies of nursing students. The use of models in sexual counseling enables students to relate theory and practice to sexual health care. In this study, sexual health training will be implemented in an innovative way by supporting the use of models in the process of providing sexual counseling to the patients of nursing students. The most commonly used PLISSIT model will be taught to nursing students while providing sexual counseling to patients and its effectiveness will be determined. In the literature, only one study was found with students on the use of the PLISSIT model in sexual health assessment. The research is planned to be pre-test post-test comparative, randomized, with one experiment and one control group, repeated measurement ın order to determine the effect of the sexual health training given to nursing students with the PLISSIT model on the myths about sexuality, sexual health care knowledge and sexual health care attitude. This research will be carried out between December 2023 and March 2024 with the participation of fourth grade students studying at Marmara University Faculty of Health Sciences, Department of Nursing. Students who is suitable the inclusion criteria will be randomized to the experimental (n=45) and control groups (n=45). The data of the research will be obtained by using "Student Information Form", "Sexual Health Care Knowledge Scale", "Sexual Health Care Attitude Scale" and "Sexual Myths Scale" and "Student Opinion Form on Sexual Health Education". Ethical permission and institutional permission were obtained.During the research, while the control group receives routine training, the experimental group will be given a sexual health assessment training including 16 hours of PLISSIT model teaching by the researcher. The data of the research will be obtained by using the data collection form before the training, immediately after the training and 3 months after the training. By ensuring that nursing students learn and practice sexual health assessment, the sexual health of individuals will be protected and improved.
Plant extract comprises a combination of proteic and glycoproteic molecules, which together form a molecular complex with a mol. wt. of 25000 daltons.  The substrate used is chosen from all plants contg. proteinic and glycoproteinic material such as potatoes, radish, cucumber, courgette, tomato, turnip, Jerusalem artichoke or marrow. The extract is pref. purified by thermocoagulation in the presence of alcohol, caprylic acid and acetic acid, followed by ultrafiltration and chromatography.
The investigators will introduce a mindfulness based stress reduction (MBSR) training program at Boston Medical Center's oncology clinic to promote engagement of low-income and minority smokers with cancer in smoking cessation. This training will follow an adapted MBSR curriculum designed by and for Boston Medical Center patients with chronic pain in the Integrated Medical Group Visit research program in Family Medicine. The investigators will tailor this adapted MBSR curriculum to address smoking cessation. To test the feasibility and acceptability of our intervention, the investigators will pilot test it with 30 patients over the course of three MBSR training programs (each cohort is 9 weeks). The investigators will acquire feasibility data (number of inquiries, number of sessions attended, and satisfaction with MBSR). Additionally, pre and post questionnaires will assess readiness to quit, stress level, and satisfaction with and acceptability of MBSR after every cohort). The primary outcome is engagement in smoking cessation treatment which includes counseling and/or pharmacotherapy. Additionally, the investigators will hold a focus group after each of the 3 cohorts have completed the program to discuss acceptability of study materials as well as facilitators and barriers to participation in the training. Data collected from this study will generate preliminary data to successfully justify and secure future funding for a larger controlled study.
Participants will be enrolled from the ongoing GFB-887 multiple ascending dose trial. Participants will be transitioned to a 200 mg QD dose level regardless of the dose received in the previous study although the data review team (DRT) and Medical Monitor may elect to decrease or increase the dose to minimize adverse events or improve clinical efficacy. The DRT may also elect to change dosing levels due to emerging data on GFB-887. Participants will take GFB-887 once daily at home. A phone visit will be conducted at Week 4 and at Week 8 to assess safety and tolerability. Participants will return to the clinic for follow up visits at Weeks 12, 24, 36, 48, and every 24 weeks thereafter through approximately 3 years from the time of the participant's first dose to evaluate long-term safety and durability of response (for up to approximately 13 scheduled in-clinic visits).
Primiparous pregnant women may need support regarding the breastfeeding process because they have not had breastfeeding experience before. Negative breastfeeding stories and misinformation can affect beliefs, attitudes, and fears about breastfeeding. Education-based interventions provided by health professionals can be beneficial in reducing false beliefs and myths about breastfeeding, reducing breastfeeding-related fears/anxious expectations, and increasing breastfeeding self-efficacy. Hypnobreastfeeding is one of the education-based interventions used in this field. This study aims to evaluate the effect of hypnobreastfeeding education given to primiparous pregnant women on breastfeeding myths, breastfeeding expectations and breastfeeding self-efficacy. According to the results of the power analysis, at least 104 pregnant women, 52 experimental and 52 control, should be included in the study. Data will be collected with the "Pregnant Introduction Form", "Breastfeeding Myths Scale", "Breastfeeding Expectations Scale-A" and "Prenatal Breastfeeding Self-Efficacy Scale". In the research, hypnobreastfeeding training will be applied by the researcher to the primiparous pregnant women in the experimental group.
OBJECTIVE: To study the association between placental efficiency with anthropometry and nutritional phenotypes in full-term newborns from a birth cohort.
METHOD: This was a secondary cross-sectional analysis of data obtained in a cohort study (Brazilian RibeirãoPreto and São Luís Birth Cohort Studies - BRISA), whose deliveries were performed between 2010 and 2011. Standardized questionnaires were applied to mothers, and placentas and newborns were evaluated shortly after delivery. Placental efficiency was assessed using the ratio between birth weight and placental weight (BW/PW ratio); values below the lower quartile (25th percentile for gestational age) were considered to have low placental efficiency. Newborn phenotypes were small and large for gestational age, stunted and wasted, evaluated using the INTERGROWTH-21 growth standard. To identify the confounding variables theoretical model was constructed using Directed Acyclic Graphs, and unadjusted and adjusted logistic regression were performed. Placental measurements were obtained blindly from pregnancy and delivery data.
RESULTS: 723 mother-placenta-child triads were studied. 3.2 % of newborns were small-for-gestational-age (SGA), 6.5 %large-for-gestational-age (LGA), 5.7 %had stunting, and 0.27 % wasting. A significantly higher risk was found between low placental efficiency and SGA (OR 2.82;95 % CI 1.05-7.57), stunting (OR 2.23; 95 % CI 1.07-4.65), and wasting (OR 8.22; 95 % CI 1.96-34.37). No relationship was found between LGA and placental efficiency.
CONCLUSIONS: Low placental efficiency was associated with increased risk for small-for-gestational-age, stunting, and wasting. Placental morphometry can provide valuable information on intrauterine conditions and neonatal health, helping to identify newborns at higher risk of future comorbidities.
One of the earliest applications of flow cytometry was the measurement of DNA content in cells. This method is based on the ability to stain DNA in a stoichiometric manner (i.e., the amount of stain is directly proportional to the amount of DNA within the cell). For more than 40years, a number of studies have consistently demonstrated the utility of DNA flow cytometry as a potential diagnostic and/or prognostic tool in patients with most epithelial tumors, including pre-invasive lesions (such as dysplasia) in the gastrointestinal tract. However, its availability as a clinical test has been limited to few medical centers due to the requirement for fresh tissue in earlier studies and perceived technical demands. However, more recent studies have successfully utilized formalin-fixed paraffin-embedded (FFPE) tissue to generate high-quality DNA content histograms, demonstrating the feasibility of this methodology. This review summarizes step-by-step methods on how to perform DNA flow cytometry using FFPE tissue and analyze DNA content histograms based on the published consensus guidelines in order to assist in the diagnosis and/or risk stratification of many different epithelial tumors, with particular emphasis on dysplasia associated with Barrett's esophagus and inflammatory bowel disease.
PURPOSE:To obtain a bathing additive capable of suppressing an offensive smell, also preventing unpleasant sliminess at the bottom part of a bathtub free from chlorine smell and corrosion of metal, etc., containing a hydroiodide such as potassium iodide, sodium iodide or lithium iodide. CONSTITUTION:A bathing additive containing a hydroiodide (e.g. magnesium iodide, calcium iodide, ammonium iodide, etc.) shown by the formula InX (n is 1 or 2; X is K, Na, Li, Mg, Ca or NH4). The amount of the additive added is 1-30ppm, more preferably 3-10ppm calculated as hydroiodide based on water for bathtub. Time for addition is effectively before bathing. Conveniently the hydroiodide is mixed wit a neutral inorganic salt as an extender and sodium methyl cellulose, etc., as a binder and formed into tablets. The bathing additive especially prevents an unpleasant offensive smell of rewarmed water in bathtub.
Parenteral, or liquid oral, compositions comprise the penicillin G salt of N,N1-dibenzylethylene diamine having a particle size 0.5 to 150 microns, the majority of the lower end of the range, the salt originally being either amorphous or microcrystalline or acicular in form, together with a water-soluble alkali metal or alkaline earth metal salt of penicillin, at least one part by weight of the water-soluble salt being present per 10 parts by weight of the diamine salt, the diamine penicillin salt being present in an amount greater than 200,000 Oxford units per c.c.  The mixture has a reduced viscosity and is more easily aspirated into, or extruded from, a hypodermic syringe than the diamine salt alone.  Other spraringly soluble salts such as procaine penicillin may be present.  The composition may be in dry form for reconstitution for use in fluid form as an aqueous or oleaginous suspension.  Isotonics, suspending agents, emulsifiers, buffers, stabilizing agents and preservatives may be present.  The diamine di-penicillin may be coated with lecithin to increase the wetting action.  Specification 716,556 is referred to.
PURPOSE: We aimed to develop a simulation program for physicians and nurses involved in virtual reality (VR) and augmented reality (AR) treatment and care from the perspective of these professionals and older adults with dementia who developed delirium, and to test the effectiveness of the program.
METHODS: effectiveness of the program was analyzed through free-response statements from 67 nurses (84.8%) and 12 doctors (15.2%) who participated in the program between February 16 and April 18, 2023.
RESULTS: Regarding the experience of delirium from the perspective of older adults with dementia (personal experience), the following statements were extracted "1. I do not understand where I am, the situation, and the treatment/care that is about to be given"; "2. I want the situation to be explained to me so that I can understand the reasons for my hospitalization and the treatment/care I am receiving"; "3. The eerie environment of the hospital and the high pressure of the staff made me feel anxious and fearful"; "4. Please respect my existence as I endure pain, anxiety, and loneliness"; "5. I feel relieved when doctors and nurses deal with me from my point of view"; and "6. I feel relieved when there is a familiar presence, such as a family member or the name I am calling on a daily basis".
CONCLUSION: Specific categories of self-oriented empathy were extracted from the experience of physical restraint at night using VR and the experience of delirium using AR. This suggests the possibility of objective effects on treatment and care in future practice.
PURPOSE:To obtain a dentifrice agent, containing oxygen in a quantity exceeding oxygen content containable at ordinary temperature under ordinary pressure, capable of suppressing propagation of anaerobic bacteria causing periodontosis and effective in preventing periodontosis. CONSTITUTION:A dentifrice agent, obtained by putting water or a solvent, e.g. glycerol, propylene glycol, ethyl alcohol, etc., ingredients used in ordinary dentifrice, e.g. polishing agent, wetting agent, binder, foaming agent or sweetener in a hermetically sealed container, e.g. bottle, can etc., and filling oxygen under pressure and containing oxygen in a quantity exceeding the oxygen content containable at ordinary temperature under ordinary pressure. Filling of oxygen under pressure is preferably carried out under the maximum 10atm pressure for the can and the maximum 5atm pressure for ordinary glass bottles.